TCGA-CV-6003-01A-11R-1686-07
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- sex
- female
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- MYC_TARGETS_V2+0.570
- MYC_TARGETS_V1+0.540
- E2F_TARGETS+0.520
- DNA_REPAIR+0.410
- INTERFERON_ALPHA_RESPONSE+0.400
- MTORC1_SIGNALING+0.400
- G2M_CHECKPOINT+0.390
- GLYCOLYSIS+0.340
- REACTIVE_OXYGEN_SPECIES_PATHWAY+0.270
- OXIDATIVE_PHOSPHORYLATION+0.260
Top 10 suppressed
- ALLOGRAFT_REJECTION-0.340
- KRAS_SIGNALING_UP-0.290
- IL6_JAK_STAT3_SIGNALING-0.280
- INFLAMMATORY_RESPONSE-0.270
- UV_RESPONSE_DN-0.250
- KRAS_SIGNALING_DN-0.240
- NOTCH_SIGNALING-0.220
- ANGIOGENESIS-0.200
- TGF_BETA_SIGNALING-0.160
- TNFA_SIGNALING_VIA_NFKB-0.120
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-A8-A07R-01A-21R-A034-07 | — | E | 0.869 |
| 2 | SRR8518179 | — | E | 0.868 |
| 3 | SRR15030853 | — | — | 0.862 |
| 4 | MNG358 | — | — | 0.858 |
| 5 | SRR25043614 | — | — | 0.856 |
| 6 | SRR6013575 | — | cohortSQ2 | 0.854 |
| 7 | TCGA-A7-A0CJ-01A-21R-A00Z-07 | — | B | 0.851 |
| 8 | TCGA-XF-A9T6-01A-11R-A42T-07 | — | — | 0.843 |
| 9 | TCGA-NC-A5HN-01A-11R-A26W-07 | — | cohortSQ2 | 0.833 |
| 10 | TCGA-GU-AATQ-01A-11R-A39I-07 | — | — | 0.832 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 22 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| MYC_TARGETS_V2 | 0.570 | Idelalisib | — uncovered |
| MYC_TARGETS_V1 | 0.540 | Inavolisib | — uncovered |
| E2F_TARGETS | 0.520 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.410 | Idelalisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.400 | Inavolisib | — uncovered |
| MTORC1_SIGNALING | 0.400 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.390 | Inavolisib | — uncovered |
| GLYCOLYSIS | 0.340 | Inavolisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.270 | Inavolisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.260 | Remibrutinib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.220 | Idelalisib | — uncovered |
| UV_RESPONSE_UP | 0.170 | Idelalisib | — uncovered |
| HYPOXIA | 0.150 | Idelalisib | — uncovered |
| APICAL_JUNCTION | 0.120 | Inavolisib | — uncovered |
| MITOTIC_SPINDLE | 0.120 | Inavolisib | — uncovered |
| ADIPOGENESIS | 0.090 | Inavolisib | — uncovered |
| PEROXISOME | 0.070 | Idelalisib | — uncovered |
| P53_PATHWAY | 0.060 | Idelalisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.050 | Idelalisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.020 | Remibrutinib | — uncovered |